Antares Therapeutics Enters Agreement with Novartis to Discover, Develop and Commercialize First-in-Class Cancer Therapies Antares Therapeutics, Inc. a biotechnology company developing first-in-class precision medicines for cancer and other serious diseases, today announced a strategic collaboration with Novartis to discover, develop…
Verici Dx Receives New York State Approval, Establishing Nationwide Access to Tutivia™ Kidney Transplant Rejection Test Verici Dx plc a developer of advanced clinical diagnostics for organ transplant, announced it has received clinical laboratory accreditation from the New York State…
Definium Therapeutics Announces Positive Topline Results from Phase 3 Emerge Study of DT120 Orally Disintegrating Tablet (ODT) in Major Depressive Disorder Definium Therapeutics, Inc. a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes…
ICON selects Microsoft as a preferred technology partner to power AI-enabled clinical development ICON plc announced that it has selected Microsoft as a preferred technology partner – further advancing ICON’s previously announced plan to invest in digital innovation and AI…
Pfizer Announces Topline Phase 3 Results for Sigvotatug Vedotin in Previously Treated Metastatic Non-Squamous Non-Small Cell Lung Cancer Pfizer Inc. announced topline results from the Phase 3 SigVie-002 study (previously known as Be6A Lung-01) evaluating sigvotatug vedotin, an investigational, potential…
BIOTECanada Opens Canada Pavilion at BIO 2026 Amid Major Policy Momentum for Canadian Biotech BIOTECanada officially opened the Canada Pavilion today at the BIO International Convention in San Diego, serving as the central hub for Canadian biotechnology companies to showcase…
Pheno Therapeutics Granted FDA IND Clearance for Lead Multiple Sclerosis Therapeutic Candidate PTD802 Pheno Therapeutics Limited. (Pheno), a clinical stage biotechnology company focused on the discovery and development of small molecule therapeutics for the treatment of neurological diseases, today announced…
Bionyra Pharma Launches with $165 million Oversubscribed Series A to Advance Clinical Stage Pipeline of Next Generation Biologics for Immune-Mediated Inflammatory Diseases Bionyra Pharma, a clinical-stage biopharmaceutical company developing next-generation biologics for immune-mediated inflammatory diseases, today announced the company’s launch…
Greenstone Biosciences, Inc. and Intel Corp. Launch Strategic Collaboration to Scale Human-Centric Drug Discovery Greenstone Biosciences, Inc. announces a collaboration with Intel Corp. to accelerate AI-enabled drug discovery using Greenstone’s large-scale, human biobank of induced pluripotent stem cells and Intel’s Edge AI advanced computing and AI infrastructure. Intel and Greenstone are working together…
New Critique by Haypp Group Warns Seizure Claims About Nicotine Pouches Overstate Animal Study Findings Giving mice a chemically induced epileptic condition and then adding nicotine does not prove that nicotine causes or worsens seizures, according to Haypp Group’srecently published…
IQM Appoints Craig Ciesla, Former Illumina VP, as CTO; Inés de Vega Becomes Chief Scientist IQM Quantum Computers, the global leader in superconducting quantum computers, announced the appointments of Dr. Craig Ciesla as Chief Technology Officer (CTO) and Dr. Inés…
101 Therapeutics Releases Clinical Evidence Package for Macrophage-Targeted 101-PGC-005 and Seeks Urgent Independent Review for Bundibugyo Ebola Disease 101 Therapeutics Ltd. today announced the public release of its clinical and scientific evidence package for 101-PGC-005 (‘005), a macrophage-targeted dexamethasone prodrug…